Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA(TM)) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection

BACKGROUND: Fecal microbiota, live-jslm (RBL; REBYOTA™), the first microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults, has been evaluated in 5 prospective clinical trials. A retrospective analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Feuerstadt, Paul, Harvey, Adam, Yoho, David S, Garcia-Diaz, Julia B, Knapple, Whitfield L, Bancke, Lindy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225279/
https://www.ncbi.nlm.nih.gov/pubmed/37256213
http://dx.doi.org/10.1093/ofid/ofad171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225279/
https://www.ncbi.nlm.nih.gov/pubmed/37256213
http://dx.doi.org/10.1093/ofid/ofad171

Ejemplares similares